Efeitos adversos no tratamento da Esclerose Múltipla com drogas imunomoduladoras
experiência em 118 casos
DOI:
https://doi.org/10.34024/rnc.2009.v17.8545Palavras-chave:
Esclerose múltipla, Imunomoduladores, Efeitos Adversos, ManejoResumo
Drogas imunomoduladoras são as mais prescritas para pacientes com esclerose múltipla, reduzindo a freqüência dos surtos e a atividade da doença, porém podem ocorrer efeitos adversos, que influenciam significativamente na aderência o tratamento. Objetivo. Relatar o perfil de efeitos adversos em pacientes medicados com imunomoduladores e as condutas adequadas para manter a adesão ao tratamento. Método. Foi realizada análise retrospectiva de 276 prontuários de pacientes do CATEM, sendo considerados aqueles em tratamento imunomodulador por um período mínimo de 5 anos. Consideramos o uso de um único imunomodulador e a migração para um segundo ou terceiro medicamento, e os efeitos classificados em leves, moderados ou graves. Resultados. Foram relatados efeitos adversos em 118 (42.7%) pacientes, 50 (42,3%) com efeitos leves, 45 (38,1%) moderados e 23 (19,4%) graves. Os efeitos adversos mais freqüentes foram reações locais em 31 (26,2%), e moderados em 17 (14,4%). Ocorreram efeitos adversos em 42 (47,7%) dos 88 pacientes com INFβ-1b SC, em 41 (54,6%) dos 75 com INFβ-1a SC, em 16 (25,8%) dos 62 com INFβ-1a IM, e em 19 (37,2%) dos 51 com acetato de glatirâmer. Conclusões. Os efeitos adversos são comuns durante o tratamento com imunomoduladores e o manejo adequado aumenta a aderência ao tratamento.
Downloads
Métricas
Referências
Turner AP, Kivlahan DR, Sloan AP, Haselkorn JK. Predicting ongoing adherence to disease modifying therapies in multiple sclerosis: utility of the health beliefs model. Mult Scler 2007;13:1146-52.
Frohman EM, Brannon K, Alexander S, Sims D, Phillips JT, O’Leary S, et al. Disease modifying agents related skin reactions in multiple sclerosis: prevention, assessment and management. Mult Scler 2004;10:302-7.
The IFN beta Multiple Sclerosis Study Group. Interferon beta 1b is effective in relapsing-remitting muyltiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43:655-61.
Jacobs LD, Cookfair DL, Rudick, Herndon RM, Richert JR, Salazar AM, et al. Intramuscular interferon beta 1-a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-94.
Mohr DC, Goodkin DE, Masuoka L, Dick LP, Russo D, Eckhardt J, et al. Treatment adherence and patient retention in the first year of a phase III clinical trial for the treatment of multiple sclerosis. Mult Scler 1999;53:192-7.
Hadjimichael O, Volmer TL. Adherence to injection therapy in multiple sclerosis: patient survey. Neurology 1999;53:1190-7.
Tremlett HL, Oger J. Interrupted therapy. Stopping and switching of the β-interferons prescribed for MS. Neurology 2003;61:551-4.
Goodin DS, Frohman EM, Garmany GP, Halper J, Likosky WH, Lublin FD, et al. Disease modifying therapies in multiple sclerosis. Neurology 2002;58:169-78.
Rio J, Porcel J, Téllez N. Factors related with adherence to interferon β and glatiramer acetate therapy in multiple sclerosis. Mult Scle 2005;11:306-9.
O΄Rourke K, Hutchinson M. Analysis of stopping patterns in INFB therapay. Mul Scler 2005;11:46-50.
Jordy SS, Tilbery CP, Fazzito MM. Immunomodulatot therapy migration in relapsing remitting multiple sclerosis. A study of 152 cases. Arq Neuropsiquiatr 2008;66:11-4.
Mohr DC, Goodking DE, Likosky W, Dwyer P. Therapeutic expectations of patients with multipla sclerosis upon iniating interferon beta -1b: relationship to adherence to treatment. Mult Scler 1996;2:222-6.
Dubois BD, Keenan E, Porter BE, Kapoor R, Rudge P, Thompson AJ, et al. Interferon beta in multiple sclerosis: .experience in a British specialist multiple sclerosis centre J Neurol Neurosurg Psychiatr 2003;74:946-9.
Baum K, Leary CO, Ferrer FC, Klímová E, Procházková L, Bugge J, et al. Comparison of injection site pain and injection site reactions in relapsing-remiting multiple sclerosis patients treated with interferon beta-1a or 1b. Mult Scler 2007;13:1153-60.
Lublin FD, Whitaker JN, Eidelman BH, Miller AE, Arnason BGW, Burks JS. Management of patients receiving interferon beta 1b for multiple sclerosis: report of a consensus conference. Neurology 1996;46:12-8.
Dayal AS, Jensen MA, Lledo A, Arnason BGW. Interferongamma-secreting cells in multiple sclerosis treated with interferon beta 1-b. Neurology 1995;45:2173-7.
Arnason BGW, Reder AT. Interferons and multiple sclerosis. Clin Neuropharmacol 1994;17:495-547.
Walter EU, Hohlfeld R. Multiple sclerosis: side effects of interferon beta therapy and their management. Neurology 1999;53:1622-7.
Munschauer FE, Kinkel RP. Managing side effects of interferon beta in patients with relapsing-remitting multiple sclerosis. Clin Ther 1997;19:883-93.
Rio J, Nos C, Marzo ME, Tintoré M, Montalban X. Low-dose steroids reduce flu-like symptoms at the initistion of INF beta 1b in relapsing-remitting MS. Neurology 1998;50:1910-2.
Agras S, Sylvester D, Oliveau D. The epidemiology of bloodinjection-injury phobia. Psychol Med 1998;28:1129-36.
Costello CG. Fears and phobias in women: a community study. J Abnorm Psychol 1982;4:280-6.
Cox D, Mohr DC. Managing difficulties with adherence to injectable medications due to blood, injection, and injury phobia and self-injection anxiety. Am J Drug Deliv 2003;1:215-21.
Vial T, Descotes J. Clinical toxicity of the interferons. Drug Safety 1994;10:115-50.
European Study Group on Interferon beta 1b in secondary progressive MS. Placebo-controlled multicentre randomized trial of interferon beta 1b in treatment of secondary progressive multiple sclerosis. Lancet 1998;352: 1491-7.
PRISMS (Prevention of relapses, disability by interferon beta 1a subcutaneously in multiple sclerosis). Study Group. Randomized double-blind placebo-controlled study of interferon beta 1 a in relapsing/remitting multipla sclerosis. Lancet 1998;352:1498-504.
Fukunishi K, Tanaka H, Marruyama J, Takahashi M, Ueshima K, Sakata I, et al. Burns in a suicide attempt related to psychiatric side effects of interferon. Burns 1998;24:581-3.
Borras C, Rio J, Porcel J, Barrios M, Tintore M, Montalben X. Emotional state of patients with relapsing-remitting MS treated with interferon beta 1b. Neurology 1999;52:1636-9.
Tremlett HL, Oger J. Ten years of adverse drug reactions reports for the multiple sclerosis immunomodulatory therapies: a Canadian perspective. Mult Scler 2008;14:94-105.
Gaines AR, Varricchio F. Interferon beta 1b injection site reactions and necroses. Mult Scler 1998;4:70-3.
Downloads
Publicado
Como Citar
Edição
Seção
Publicado: 2009-09-30
Português
English
Español
